CN101588807B - D-核糖在制备治疗心律失常的药物中的应用 - Google Patents
D-核糖在制备治疗心律失常的药物中的应用 Download PDFInfo
- Publication number
- CN101588807B CN101588807B CN2008800029553A CN200880002955A CN101588807B CN 101588807 B CN101588807 B CN 101588807B CN 2008800029553 A CN2008800029553 A CN 2008800029553A CN 200880002955 A CN200880002955 A CN 200880002955A CN 101588807 B CN101588807 B CN 101588807B
- Authority
- CN
- China
- Prior art keywords
- ribose
- grams
- purposes
- gram
- cardiac arrhythmias
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title claims abstract description 49
- 206010003119 arrhythmia Diseases 0.000 title description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 24
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 24
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 7
- 238000011866 long-term treatment Methods 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 208000008510 paroxysmal tachycardia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004213 regulation of atrial cardiomyocyte membrane depolarization Effects 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88194007P | 2007-01-23 | 2007-01-23 | |
| US60/881,940 | 2007-01-23 | ||
| PCT/US2008/000845 WO2008091618A1 (en) | 2007-01-23 | 2008-01-23 | Use of d-ribose to treat cardiac arrhythmias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101588807A CN101588807A (zh) | 2009-11-25 |
| CN101588807B true CN101588807B (zh) | 2012-07-04 |
Family
ID=39264528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800029553A Active CN101588807B (zh) | 2007-01-23 | 2008-01-23 | D-核糖在制备治疗心律失常的药物中的应用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8101581B2 (enExample) |
| EP (1) | EP2120968B1 (enExample) |
| JP (1) | JP5396387B2 (enExample) |
| CN (1) | CN101588807B (enExample) |
| AT (1) | ATE487485T1 (enExample) |
| BR (1) | BRPI0806231A2 (enExample) |
| CA (1) | CA2674717C (enExample) |
| DE (1) | DE602008003411D1 (enExample) |
| ES (1) | ES2352154T3 (enExample) |
| WO (1) | WO2008091618A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020119933A1 (en) * | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
| JP5396387B2 (ja) | 2007-01-23 | 2014-01-22 | バイオエナジー インコーポレイティド | 心臓不整脈を治療するためのｄ−リボースの用途 |
| CN106138071A (zh) * | 2008-04-02 | 2016-11-23 | 生物能公司 | 核糖在对于急性心肌梗塞的第一反应中的用途 |
| EP3411041A1 (en) | 2016-02-01 | 2018-12-12 | RiboCor, Inc. | Use of ribose for treatment of subjects having congestive heart failure |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605644A (en) | 1985-02-07 | 1986-08-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia employing ribose and adenine |
| US4719201A (en) | 1985-02-07 | 1988-01-12 | Regents Of The University Of Minnesota | Method for stimulating recovery from ischemia |
| US4824660A (en) | 1985-06-06 | 1989-04-25 | Paul S. Angello | Method of determining the viability of tissue in an organism |
| DE4228215A1 (de) | 1992-08-25 | 1994-03-03 | Pliml Wolfgang | Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen |
| RU2127548C1 (ru) | 1996-06-26 | 1999-03-20 | Алабовский Владимир Владимирович | Способ коронарографии в эксперименте |
| DE19650754A1 (de) * | 1996-12-06 | 1998-06-10 | Wolfgang Dr Pliml | Ribose und Schlaganfall |
| US6159942A (en) | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
| US6218366B1 (en) | 1998-06-19 | 2001-04-17 | Bioenergy, Inc. | Method for raising the hypoxic threshold |
| US6429198B1 (en) | 1999-04-12 | 2002-08-06 | Bioenergy Inc. | Compositions for increasing athletic performance in mammals |
| US20020119933A1 (en) | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
| US6534480B2 (en) | 1999-06-17 | 2003-03-18 | Bioenergy Inc. | Compositions for increasing energy in vivo |
| US6511964B2 (en) | 1999-09-24 | 2003-01-28 | Bioenergy, Inc. | Method for treating acute mountain sickness |
| US6159943A (en) | 1999-09-24 | 2000-12-12 | Bioenergy, Inc. | Use of ribose to prevent cramping and soreness in muscles |
| US6339716B1 (en) | 1999-09-24 | 2002-01-15 | Bioenergy Inc. | Method for determining viability of a myocardial segment |
| US6703370B1 (en) | 1999-10-27 | 2004-03-09 | Bioenergy, Inc. | Use of ribose to treat fibromyalgia |
| JP4927282B2 (ja) | 1999-12-21 | 2012-05-09 | バイオエナジー インコーポレイティド | 血小板の保存のための組成物 |
| CA2397707A1 (en) | 2000-01-07 | 2001-07-19 | Susan S. Percival | Compositions for enhancing the immune response |
| US6525027B2 (en) | 2000-01-20 | 2003-02-25 | Bioenergy Inc. | Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans |
| US6420342B1 (en) | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| IT1317043B1 (it) * | 2000-06-14 | 2003-05-26 | Sigma Tau Healthscience Spa | Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio. |
| US20030212006A1 (en) | 2002-05-13 | 2003-11-13 | Seifert John G. | Method for reducing free radical formation in healthy individuals undergoing hypoxic exercise and medical conditions with increased oxygen free radicals |
| US8486859B2 (en) | 2002-05-15 | 2013-07-16 | Bioenergy, Inc. | Use of ribose to enhance plant growth |
| US7687468B2 (en) | 2003-05-14 | 2010-03-30 | Viacell, LLC. | Rejuvenation of stored blood |
| US8759315B2 (en) | 2003-05-14 | 2014-06-24 | Viacell, Llc | Methods for rejuvenating |
| US20040229205A1 (en) | 2003-05-16 | 2004-11-18 | Ericson Daniel G. | Compositions for the storage of platelets |
| US20090197818A1 (en) | 2004-01-14 | 2009-08-06 | St Cyr John A | Use Of Ribose for Recovery From Anaesthesia |
| WO2005107768A2 (en) | 2004-04-29 | 2005-11-17 | Bioenergy, Inc. | Method for improving ventilatory efficiency |
| US20100099630A1 (en) | 2004-04-29 | 2010-04-22 | Maccarter Dean J | Method for improving ventilatory efficiency |
| PT1800675E (pt) * | 2005-12-23 | 2011-08-30 | Nutricia Nv | COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA |
| US8835396B2 (en) | 2006-12-15 | 2014-09-16 | Bioenergy, Inc. | Method and compositions for improving pulmonary hypertension |
| JP5396387B2 (ja) | 2007-01-23 | 2014-01-22 | バイオエナジー インコーポレイティド | 心臓不整脈を治療するためのｄ−リボースの用途 |
| US20090197819A1 (en) | 2007-03-20 | 2009-08-06 | Clarence Albert Johnson | Compositions for improving and repairing skin |
| US20080312169A1 (en) | 2007-03-20 | 2008-12-18 | Clarence Albert Johnson | Cosmetic use of D-ribose |
| US20090232750A1 (en) | 2008-03-13 | 2009-09-17 | St Cyr John A | Compositions for indoor tanning |
| CN106138071A (zh) | 2008-04-02 | 2016-11-23 | 生物能公司 | 核糖在对于急性心肌梗塞的第一反应中的用途 |
| US20090286750A1 (en) | 2008-05-16 | 2009-11-19 | Kasubick Robert V | Use of ribose in lessening the clinical symptoms of aberrant firing of neurons |
-
2008
- 2008-01-23 JP JP2010517230A patent/JP5396387B2/ja active Active
- 2008-01-23 CN CN2008800029553A patent/CN101588807B/zh active Active
- 2008-01-23 DE DE602008003411T patent/DE602008003411D1/de active Active
- 2008-01-23 EP EP08713225A patent/EP2120968B1/en active Active
- 2008-01-23 CA CA2674717A patent/CA2674717C/en active Active
- 2008-01-23 BR BRPI0806231-5A patent/BRPI0806231A2/pt not_active IP Right Cessation
- 2008-01-23 WO PCT/US2008/000845 patent/WO2008091618A1/en not_active Ceased
- 2008-01-23 ES ES08713225T patent/ES2352154T3/es active Active
- 2008-01-23 AT AT08713225T patent/ATE487485T1/de active
- 2008-01-23 US US12/009,933 patent/US8101581B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 刘平怀等.D-核糖对实验性心肌缺血和心律失常的作用研究.《中国药业》.2005,第14卷(第10期),26－28. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080176809A1 (en) | 2008-07-24 |
| EP2120968A1 (en) | 2009-11-25 |
| ES2352154T3 (es) | 2011-02-16 |
| US8101581B2 (en) | 2012-01-24 |
| CA2674717A1 (en) | 2008-07-31 |
| WO2008091618A8 (en) | 2010-04-01 |
| ATE487485T1 (de) | 2010-11-15 |
| DE602008003411D1 (de) | 2010-12-23 |
| CA2674717C (en) | 2015-10-13 |
| BRPI0806231A2 (pt) | 2011-09-06 |
| JP2010526884A (ja) | 2010-08-05 |
| EP2120968B1 (en) | 2010-11-10 |
| JP5396387B2 (ja) | 2014-01-22 |
| WO2008091618A1 (en) | 2008-07-31 |
| CN101588807A (zh) | 2009-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leenhardt et al. | Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. | |
| Garson Jr et al. | Junctional ectopic tachycardia in children: electrocardiography, electrophysiology and pharmacologic response | |
| Eldar et al. | Permanent cardiac pacing in patients with the long QT syndrome | |
| Desautels et al. | Ventricular tachycardia associated with administration of thioridazine hydrochloride (Mellaril): report of a case with a favourable outcome | |
| CN101588807B (zh) | D-核糖在制备治疗心律失常的药物中的应用 | |
| Sagie et al. | Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers | |
| Sandler et al. | Use of oxprenolol in cardiac arrhythmias associated with acute myocardial ischaemia | |
| Dreifus et al. | Propranolol and quinidine in the management of ventricular tachycardia | |
| Sakamoto et al. | Sequential use of aminophylline and theophylline for the treatment of atropine-resistant bradycardia after spinal cord injury: a case report | |
| Brugada et al. | Suppression of incessant supraventricular tachycardia by intravenous and oral encainide | |
| Dronacharya et al. | Lightning induced atrial fibrillation | |
| Albrecht et al. | Cardiovascular side-effects of lithium | |
| McVay et al. | Idiopathic long QT syndrome: Association of ventriculartachycardia with alternating left and right bundle branch block | |
| Al-Alwany et al. | His-Ventricle (HV) Interval And Syncope As Predictor For Pacemaker Implantation In Patients With Bifascicular Block (BFB) | |
| Greenspon et al. | Hereditary long QT syndrome associated with cardiac conduction system disease | |
| Hayashi et al. | Alcohol‐induced ventricular fibrillation in Brugada syndrome | |
| Gould et al. | One monitored case of sudden death | |
| Kubik et al. | Practolol and Dextro-Propranolol in Prophylaxis of Post Infarction Arrhythmias | |
| Young et al. | Symptomatic sinus arrest in a young girl. | |
| Sheyin et al. | High grade atrioventricular block presenting with cardiac arrest | |
| Benatar, A., Hill, ID, Fraser, CB & Human | The prolonged QT syndrome in childhood-case reports | |
| Aizawa et al. | Intracoronary acetylcholine-induced prolongation of the QT Interval and torsade des pointes in long QT interval syndrome | |
| Cho et al. | An unusual case of exercise-induced idiopathic Brugada electrocardiographic pattern | |
| CN107648238A (zh) | 一种治疗阵发性室上性心动过速的盐酸普罗帕酮片组合物 | |
| Mondal et al. | Jervell-Lange Nielsen syndrome in a family with the long QT Syndrome (LQTS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: RIBERK INC. Free format text: FORMER NAME: BIOENERGY INC. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: The University of Minnesota Patentee after: Ribek Co. Address before: The University of Minnesota Patentee before: Bioenergy Inc. |